CN102753574B - 用于免疫治疗和抗肿瘤治疗的缀合物和组合物 - Google Patents

用于免疫治疗和抗肿瘤治疗的缀合物和组合物 Download PDF

Info

Publication number
CN102753574B
CN102753574B CN201080061939.9A CN201080061939A CN102753574B CN 102753574 B CN102753574 B CN 102753574B CN 201080061939 A CN201080061939 A CN 201080061939A CN 102753574 B CN102753574 B CN 102753574B
Authority
CN
China
Prior art keywords
fusion protein
cells
component
present
hil15
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080061939.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102753574A (zh
Inventor
佩德罗·贝拉翁多洛佩斯
杰西卡·菲奥拉万蒂
何塞·麦地那埃切韦尔斯
伊格纳西奥哈维尔·梅莱罗贝尔梅霍
马里亚德尔卡门·奥乔亚涅托
弗朗西斯科德阿西斯·帕拉松加里卡
西尔维亚·布尔福内波斯
欧文·汉斯·道尔特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RES CT BORSTE
Proyecto de Biomedicina CIMA SL
Original Assignee
RES CT BORSTE
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200931158A external-priority patent/ES2362062B1/es
Application filed by RES CT BORSTE, Proyecto de Biomedicina CIMA SL filed Critical RES CT BORSTE
Publication of CN102753574A publication Critical patent/CN102753574A/zh
Application granted granted Critical
Publication of CN102753574B publication Critical patent/CN102753574B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201080061939.9A 2009-12-11 2010-12-10 用于免疫治疗和抗肿瘤治疗的缀合物和组合物 Expired - Fee Related CN102753574B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (es) 2009-12-11 2009-12-11 Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ESP200931158 2009-12-11
ES201030813 2010-05-27
ESP201030813 2010-05-27
PCT/ES2010/070818 WO2011070214A2 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral

Publications (2)

Publication Number Publication Date
CN102753574A CN102753574A (zh) 2012-10-24
CN102753574B true CN102753574B (zh) 2015-05-20

Family

ID=43927978

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080061939.9A Expired - Fee Related CN102753574B (zh) 2009-12-11 2010-12-10 用于免疫治疗和抗肿瘤治疗的缀合物和组合物

Country Status (11)

Country Link
US (1) US8771664B2 (https=)
EP (1) EP2511294B1 (https=)
JP (1) JP5784626B2 (https=)
CN (1) CN102753574B (https=)
AU (1) AU2010329805B2 (https=)
BR (1) BR112012013868A8 (https=)
CA (1) CA2783876C (https=)
ES (1) ES2463016T3 (https=)
MX (1) MX2012006691A (https=)
RU (1) RU2597989C2 (https=)
WO (1) WO2011070214A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US11401312B2 (en) * 2013-04-19 2022-08-02 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
WO2015054701A2 (en) * 2013-10-13 2015-04-16 Nova Southeastern University Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders, identification of a natural killer cell population as a potential therapeutic target for gulf war illness & myalgic encephalomyelitis/chronic fatigue syndrome, and modulation of natural killer cell function by stimulation with interleukin 15
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
PL3094351T3 (pl) * 2014-01-15 2022-06-27 Kadmon Corporation, Llc Środki immunomodulujące
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US10464982B2 (en) 2014-04-23 2019-11-05 Emory University Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
EP3307783B1 (en) * 2015-06-10 2021-01-06 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
WO2023064469A1 (en) * 2021-10-13 2023-04-20 Modernatx, Inc. Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
WO2024036145A1 (en) * 2022-08-07 2024-02-15 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6408586A (en) * 1985-10-03 1987-04-24 Biotechnology Research Partners Limited Novel lipoprotein-based drug-delivery systems
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
CA2214649C (en) 1995-03-08 2007-06-12 Zeling Cai Antigen presenting system and methods for activation of t-cells
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
AU2008201887B2 (en) * 2000-11-10 2011-06-30 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
BR0115257A (pt) 2000-11-10 2003-08-12 Proteopharma Aps Análogos de apolipoproteìna
US8097283B2 (en) 2004-01-15 2012-01-17 Mount Sinai School Of Medicine Methods and compositions for imaging
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP2049560B1 (en) 2006-07-13 2013-05-15 Novozymes Biopharma DK A/S Process for preparing particles of proteinaceous material
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Combined IL-15/IL-15R alpha immunotherapy maximizes IL-15 activity in vivo;STOKLASEK THOMAS A 等;《JOURNAL OF IMMUNOLOGY》;20061231;第177卷(第9期);6072-6080 *
Competitive inhibition of LDL binding and uptake by HDL in aortic endothelial cells;ALEXANDER J J 等;《JOURNAL OF SURGICAL RESEARCH》;19901231;第49卷(第3期);248-251 *
High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer;BESSARD ANNE 等;《MOLECULAR CANCER THERAPEUTICS》;20091231;第8卷(第9期);2736-2745 *
Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8(+)/CD44(high) T cells and its antitumor action;DUBOIS SIGRID 等;《JOURNAL OF IMMUNOLOGY》;20081231;第180卷(第4期);2099-2106 *

Also Published As

Publication number Publication date
ES2463016T3 (es) 2014-05-27
WO2011070214A8 (es) 2011-09-29
WO2011070214A3 (es) 2011-08-04
AU2010329805B2 (en) 2016-07-14
BR112012013868A2 (pt) 2017-01-10
US8771664B2 (en) 2014-07-08
US20120244118A1 (en) 2012-09-27
AU2010329805A1 (en) 2012-07-05
RU2012129208A (ru) 2014-01-20
CA2783876C (en) 2018-04-03
WO2011070214A2 (es) 2011-06-16
MX2012006691A (es) 2013-02-26
JP2013513377A (ja) 2013-04-22
RU2597989C2 (ru) 2016-09-20
EP2511294B1 (en) 2014-02-26
BR112012013868A8 (pt) 2017-12-26
CN102753574A (zh) 2012-10-24
JP5784626B2 (ja) 2015-09-24
EP2511294A2 (en) 2012-10-17
CA2783876A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
CN102753574B (zh) 用于免疫治疗和抗肿瘤治疗的缀合物和组合物
EP3307783B1 (en) Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
ES2315008T3 (es) Composiciones que contienen un agente de union a receptor ox-40 o un acido nucleido que codifica el mismo y procedimientos para potenciar la respuesta inmune especifica de antigeno.
JP7250790B2 (ja) Ｉｌ－２ムテインおよびその使用
US20200283498A1 (en) T cell receptor fusions and conjugates and methods of use thereof
US9464127B2 (en) Fusion molecules and IL-15 variants
WO2012127464A2 (en) Constitutively activated t cells for use in adoptive cell therapy
CA2268752A1 (en) Plasmids encoding immunogenic proteins and intracellular as follows
JP2026027331A (ja) Ｉｌ２アゴニスト
MX2010012746A (es) Molecula adaptadora para la administracion de vectores de adenovirus.
WO2018162450A1 (en) New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
EP2374813A1 (en) Use of phenol-soluble modulins for vaccine development
ES2362062A1 (es) Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ES2348674T3 (es) Miembros de la familia del receptor similar a ig leucociteno modificado (lir) con afinidad incrementada para mhc clase i y sus usos en la modulaciã“n de la activaciã“n de cã‰lula t.
US20210008167A1 (en) T cell receptor fusions and conjugates and methods of use thereof
RU2832154C2 (ru) Варианты рецептора интерлейкина-2 (il2r) и интерлейкина-2 (il2) для специфической активации иммунных эффекторных клеток

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150520

Termination date: 20201210